New immunotherapy drug showing promise for aggressive type of breast cancer
The trial, at hundreds of sites in 41 countries, followed 902 patients and studied the combination of immunotherapy and chemotherapy (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - October 21, 2018 Category: Consumer Health News Source Type: news

Study says drug could help women with aggressive type of breast cancer
A new study shows a drug targeting the immune system could help women with an aggressive type of breast cancer. The results were announced at a conference in Europe and could change the way women are treated. Dr. Jon LaPook reports. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - October 21, 2018 Category: Consumer Health News Source Type: news

Immunotherapy scores a first win against some breast cancers
A newer immunotherapy drug for the first time has shown promise against breast cancer in a large study that combined it with chemotherapy to treat an aggressive form of the disease (Source: ABC News: Health)
Source: ABC News: Health - October 20, 2018 Category: Consumer Health News Tags: Health Source Type: news

Roche scores win in slowing aggressive type of breast cancer
An immunotherapy cocktail from Roche helped slow an aggressive type of breast cancer where new treatments have proven elusive, offering positive news for the Swiss drugmaker as it chases medicines produced by its rivals. (Source: Reuters: Health)
Source: Reuters: Health - October 20, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Immunotherapy-chemo combo extends life for women with aggressive form of breast cancer, study finds
A combination of chemotherapy and immunotherapy added months to the lives of women with triple-negative breast cancer, an aggressive type that attacks women under 50. (Source: CNN.com - Health)
Source: CNN.com - Health - October 20, 2018 Category: Consumer Health News Source Type: news

New Hope in Triple Negative Breast Cancer with Immunotherapy New Hope in Triple Negative Breast Cancer with Immunotherapy
For the first time, a survival benefit with immunotherapy has been shown in breast cancer with atezolizumab plus chemotherapy in triple negative patients.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 20, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Roche's Tecentriq boosts survival in triple-negative breast cancer
An immunotherapy cocktail from Roche helped slow a type of breast cancer where new treatments have proven elusive, data released on Saturday showed, offering positive news for the Swiss drugmaker as it chases medicines produced by its rivals. (Source: Reuters: Health)
Source: Reuters: Health - October 20, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Novartis drug cut death risk by 35 percent in gene mutation breast cancer
An experimental cancer drug that Novartis hopes will raise the profile of its oncology portfolio cut the risk of death or disease progression by more than a third in breast cancer patients with a hard-to-target gene mutation. (Source: Reuters: Health)
Source: Reuters: Health - October 20, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Immune-Based Treatment Helps Fight Aggressive Breast Cancer, Study Finds
Combining immunotherapy and chemotherapy can help women with an aggressive type of breast cancer and should become their new standard of care. (Source: NYT Health)
Source: NYT Health - October 20, 2018 Category: Consumer Health News Authors: DENISE GRADY Tags: Breast Cancer Clinical Trials Immune System Immunotherapy Nobel Prizes Chemotherapy Genentech Inc Roche Holding AG Tecentriq Source Type: news

A New Type of Treatment Shows Promise Against Aggressive Breast Cancer
This study is proof of principle that we should keep going,” Litton says. She is investigating whether there is a way for people who have already started chemotherapy to learn whether they will respond to the standard cycle of chemotherapy drugs, or should be switched to immunotherapy combinations for better results. Adams is also hopeful that other immunotherapy drugs may be developed that are more effective in activating the immune system against breast cancer cells specifically. “I expect these results will really invigorate the field and bring new research to help patients,” she says. (Source: TIME: Health)
Source: TIME: Health - October 20, 2018 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized breast cancer news healthytime Source Type: news

Roche ’s Tecentriq in combination with Abraxane improves outcomes as an initial treatment for people with PD-L1-positive metastatic triple-negative breast cancer
Roche today announced positive results from the Phase III IMpassion130 study of Tecentriq ® (atezolizumab) plus chemotherapy (Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial (first-line) treatment of unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). (Source: Roche Investor Update)
Source: Roche Investor Update - October 20, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with Abraxane improves outcomes as an initial treatment for people with PD-L1-positive metastatic triple-negative breast cancer
Roche today announced positive results from the Phase III IMpassion130 study of Tecentriq ® (atezolizumab) plus chemotherapy (Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial (first-line) treatment of unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). (Source: Roche Media News)
Source: Roche Media News - October 20, 2018 Category: Pharmaceuticals Source Type: news

Medical News Today: Using light to destroy metastatic breast cancer
Metastatic breast cancer may soon be treated using light to activate photo-sensitive drugs which, in turn, can target cancer cells and avoid healthy ones. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 20, 2018 Category: Consumer Health News Tags: Breast Cancer Source Type: news

First immunotherapy success for triple-negative breast cancer
(Queen Mary University of London) New research led by Queen Mary University of London and St Bartholomew's Hospital has shown that by using a combination of immunotherapy and chemotherapy the body's own immune system can be tuned to attack triple-negative breast cancer, extending survival (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 20, 2018 Category: International Medicine & Public Health Source Type: news

Husband and wife BOTH diagnosed with breast cancer within weeks of each other
Ken and Jane Gremling have shared everything since they got married in 1971, just three weeks after they started dating. But they never expected to receive identical breast cancer diagnoses. (Source: the Mail online | Health)
Source: the Mail online | Health - October 19, 2018 Category: Consumer Health News Source Type: news

Recognizing Nonadherence to Tamoxifen in Early Breast Cancer Patients
In premenopausal patients with early breast cancer, approximately one-sixth are not adequately adherent to adjuvant endocrine therapy. (Source: CancerNetwork)
Source: CancerNetwork - October 19, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Black women are 42% more likely to die of breast cancer than white women in the US 
Two biology researchers from Georgia State University describe the racial gap, why it eludes scientists, and what we are learning about how to close the gap. (Source: the Mail online | Health)
Source: the Mail online | Health - October 19, 2018 Category: Consumer Health News Source Type: news

Our Macclesfield office holds a Pink Party in aid of breast cancer
More than 55,000 women in the UK are diagnosed with breast cancer each year, which equates to a staggering 1 in 8 women being diagnosed at some stage... The post Our Macclesfield office holds a Pink Party in aid of breast cancer appeared first on Ashfield Healthcare. (Source: Ashfield Healthcare News)
Source: Ashfield Healthcare News - October 19, 2018 Category: Pharmaceuticals Authors: Ashfield Healthcare Communications Source Type: news

Mylan and Biocon Announce Positive CHMP Opinion for Ogivri(R), Biosimilar Trastuzumab
HERTFORDSHIRE, England, PITTSBURGH and BENGALURU, India, Oct. 19, 2018 -- (Healthcare Sales & Marketing Network) -- Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the European Medicines Agency's Committee for... Biopharmaceuticals, Generics, Oncology, Regulatory Mylan, Biocon, Ogivri, Herceptin, trastuzumab, breast cancer, biosimilar (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 19, 2018 Category: Pharmaceuticals Source Type: news

Should the BI-RADS 3 ultrasound category be revised?
Should the current BI-RADS 3 ultrasound category -- covering breast lesions...Read more on AuntMinnie.comRelated Reading: Contrast ultrasound helps characterize breast lesions Can dedicated breast PET identify suspicious lesions? Ultrasound elastography helps identify invasive breast cancer Can AI enhance the utility of breast conebeam CT? CAD software speeds up ABUS interpretationsComments: 10/19/2018 1:08:19 AMHospital-Rad They mentioned that 29% of biopsy results were uncertain? What the heck is that?  I am surprised that these articles are published.  (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 19, 2018 Category: Radiology Source Type: news

Outcomes With Celecoxib and Aspirin in AI-Treated Patients Outcomes With Celecoxib and Aspirin in AI-Treated Patients
Does short-term celecoxib or low-dose aspirin use decrease risk of breast cancer recurrence?Journal of the National Cancer Institute (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 19, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Pregnancy possible after chemotherapy for breast cancer patients, but many no longer wish
(European Society for Medical Oncology) Chemotherapy is known to have a negative impact on the reproductive potential of young breast cancer patients. Its effects on women's post-treatment fertility, however, are still poorly understood. A study to be presented at the ESMO 2018 Congress in Munich, has confirmed that natural pregnancies are possible after chemotherapy but that survivors' desire to have children decreases greatly after treatment, calling into question the need for systematic recourse to fertility preservation measures. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 19, 2018 Category: Cancer & Oncology Source Type: news

HER2+ early breast cancers where shorter-course trastuzumab could be an option
(European Society for Medical Oncology) Women with HER2-positive early breast cancer with small tumours have similar disease-free survival and lower risk of cardiac toxicity with a nine-week course of adjuvant trastuzumab compared to those treated for one year, according to a subgroup analysis of the Short-HER trial reported at ESMO 2018 Congress in Munich. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 19, 2018 Category: Cancer & Oncology Source Type: news

Living With Cancer: Do you need a 3D mammogram?
3D mammogram? Pink shirts and ribbons abound, which means it's National Breast Cancer Awareness Month. And today ? Friday, Oct. 19, is National Mammography Day, as well. If you're due for a mammogram, should you opt for a 3D mammogram? The images collected during a 3D mammogram are synthesized by a computer to form a [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - October 19, 2018 Category: Databases & Libraries Source Type: news

NICE rejects breast cancer drug for NHS funding
Decision now open to public consultation Related items fromOnMedica NICE rejects adjuvant use of breast cancer drug New breast cancer drug ‘unaffordable’ for NHS Cancer strategies failed to improve one-year survival Is crowdfunding for cancer patients paying for ‘quackery’? New cancer drug ‘refused’ by NICE (Source: OnMedica Latest News)
Source: OnMedica Latest News - October 19, 2018 Category: UK Health Source Type: news

Researchers Want Cancer Patients To Share Their Medical Information In Search of Cures
April Doyle, a single mom from Visalia, Cal., only lets herself look three months into her future. Since she was first diagnosed with breast cancer in 2014, she’s tried a new treatment every three months to keep the cancer from spreading from her breast tissue to other parts of her body. But it returned: this time in her bone. She is almost out of options for her hard-to-treat cancer, but she finds comfort in online support groups where other women with metastatic breast cancer share their experiences. “Eventually we know we will exhaust all of our options until they keep coming up with more treatments,” ...
Source: TIME: Health - October 18, 2018 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Cancer healthytime Source Type: news

Breast cancer drug ‘offers precious extra months of life’ by slowing rate of tumour growth
Afinitor is billed as the biggest advance for sufferers in years after a study found it could halt the growth of tumours or even shrink them for nearly eight months. (Source: the Mail online | Health)
Source: the Mail online | Health - October 18, 2018 Category: Consumer Health News Source Type: news

WATCH: Why black women have worse breast cancer outcomes
Here's what you need to know about breast cancer disparities, and why do they still exist? (Source: ABC News: Health)
Source: ABC News: Health - October 18, 2018 Category: Consumer Health News Tags: Health Source Type: news

Breast Tomosynthesis Better Than Mammography? Breast Tomosynthesis Better Than Mammography?
A simplified, single-view version of digital breast tomosynthesis may increase the detection of breast cancer over standard digital mammography, with lower radiation exposure, say Swedish scientists.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 18, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Living With Cancer: Flat Out: Rejecting Breast Reconstruction
After a double mastectomy, Catherine Guthrie wanted to retain her strength and challenge the idea of feminine norms. (Source: NYT Health)
Source: NYT Health - October 18, 2018 Category: Consumer Health News Authors: SUSAN GUBAR Tags: Breast Cancer Women and Girls Mastectomy Surgery and Surgeons Muscles Source Type: news

Biomarker May Predict Breast Cancer Relapse Biomarker May Predict Breast Cancer Relapse
NR2F1 expression may indicate whether or not a breast cancer patient's original tumor has metastasized to bone, researchers suggest.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - October 18, 2018 Category: Pathology Tags: Hematology-Oncology News Source Type: news

One in six premenopausal early breast cancer patients do not adhere to hormonal therapy
(European Society for Medical Oncology) Nearly one in six premenopausal women being treated for early stage breast cancer do not adhere adequately to tamoxifen therapy after one year of treatment, potentially putting themselves at increased risk of recurrence and reduced survival, a French prospective study reports at ESMO 2018. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 18, 2018 Category: Cancer & Oncology Source Type: news

Case Comprehensive Cancer Center receives $3 million NIH grant for health disparities research
(Case Western Reserve University) The Case Comprehensive Cancer Center has received a three-year, $3,194,947 grant from the National Cancer Institute to investigate colorectal and breast cancer health disparities. The grant is one of only four Specialized Programs of Research Excellence (SPORE) Planning Grant P20 awards given across the nation to address health disparities. It will provide the infrastructure for a new, comprehensive research program at Case Western Reserve School of Medicine to study cancer health disparities at molecular and population levels. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 18, 2018 Category: Cancer & Oncology Source Type: news

Case Comprehensive Cancer Center receives $3M NIH grant for health disparities research
(Case Western Reserve University) The Case Comprehensive Cancer Center has received a three-year, $3,194,947 grant from the National Cancer Institute to investigate colorectal and breast cancer health disparities. The grant is one of only four Specialized Programs of Research Excellence (SPORE) Planning Grant P20 awards given across the nation to address health disparities. It will provide the infrastructure for a new, comprehensive research program at Case Western Reserve School of Medicine to study cancer health disparities at molecular and population levels. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 18, 2018 Category: International Medicine & Public Health Source Type: news

New statistical method estimates time to metastasis of breast cancer in US women
(American Association for Cancer Research) A statistical method could fill the gaps in the US cancer registry data to estimate the short- and long-term risk of recurrence of hormone receptor (HR)-positive and HR-negative breast cancers. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 18, 2018 Category: International Medicine & Public Health Source Type: news

Women's Wellness: What do you know about having a breast biopsy?
A breast biopsy??is a way to evaluate a suspicious area in your breast to determine whether it is breast cancer. There are several types of breast biopsy procedures. A breast biopsy provides a sample of tissue that doctors use to identify and diagnose abnormalities in the cells that make up breast lumps, other unusual breast [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - October 18, 2018 Category: Databases & Libraries Source Type: news

Woman diagnosed with breast cancer for second time after hair stylist found a bald spot on her HEAD
Patricia Bolle, 68, of Haslett, Michigan, is fighting her second round of breast cancer after her hair stylist found a bald spot on her head that turned out to be breast cancer. (Source: the Mail online | Health)
Source: the Mail online | Health - October 17, 2018 Category: Consumer Health News Source Type: news

Dual HER2-Targeting in the Adjuvant Setting: Where We Have Been and Where We Are Going
This article discusses the advances in HER2-targeted therapy, in both the metastatic and adjuvant settings, with a focus on those with early-stage breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - October 17, 2018 Category: Cancer & Oncology Authors: Anureet C. Copeland, MD, Carey K. Anders, MD Source Type: news

Gene Expression Assays in Early-Stage Breast Cancer
Dr. Sparano discusses the implications of TAILORx, the first trial to use Oncotype DX in clinical decision making. (Source: CancerNetwork)
Source: CancerNetwork - October 17, 2018 Category: Cancer & Oncology Authors: Joseph A. Sparano, MD Source Type: news

Approaching Use of CDK4/6 Inhibitors in Metastatic HR+, HER2- Breast Cancer
An otherwise healthy 58-year-old woman with a history of breast cancer presents to the clinic with newly diagnosed metastatic disease; eventual abdominal CT showed a mass in the transverse colon with ascites and peritoneal nodularity. What is the best initial systemic treatment for her? (Source: CancerNetwork)
Source: CancerNetwork - October 17, 2018 Category: Cancer & Oncology Authors: Jennifer Weiss, MD, Anosheh Afghahi, MD, Elena Shagisultanova, MD, PhD, Jennifer R. Diamond, MD Source Type: news

How Close Is DBT-ABVS Accuracy to MRI for Breast Cancer Screening?
Tomosynthesis plus breast volume scanner could be replacement for breast cancer staging if MRI cannot be performed. (Source: Diagnostic Imaging)
Source: Diagnostic Imaging - October 17, 2018 Category: Radiology Authors: Diagnostic Imaging Staff Tags: Breast Imaging MRI Source Type: news

Study: Protein marker ID'd that can predict whether metastatic cancer will turn deadly
A newly identified protein could help predict whether lethal, metastatic cancer will develop in breast cancer patients, according to new research. (Source: Health News - UPI.com)
Source: Health News - UPI.com - October 17, 2018 Category: Consumer Health News Source Type: news

WATCH: Male breast cancer survivor shares his journey
Dr. Jennifer Ashton discusses what everyone should know about male breast cancer and "GMA" talks to survivors as the new ABC drama "A Million Little Things" shines a light on the disease. (Source: ABC News: Health)
Source: ABC News: Health - October 17, 2018 Category: Consumer Health News Tags: GMA Source Type: news

UC researcher fighting breast cancer with light therapy
(University of Cincinnati Academic Health Center) Nalinikanth Kotagiri, M.D., Ph.D., is studying ways ultraviolet light can activate light-sensitive drugs to treat metastatic breast cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 17, 2018 Category: Cancer & Oncology Source Type: news

FDA Approves Talzenna (talazoparib) for gBRCAm HER2-Negative Locally Advanced or Metastatic Breast Cancer
On October 16, 2018, the Food and Drug Administration approved talazoparib (Talzenna, Pfizer Inc.), a poly (ADP-ribose) polymerase (PARP) inhibitor, for patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm),... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 17, 2018 Category: Drugs & Pharmacology Source Type: news

Confirmed AGAIN: Sodium nitrite preservative in processed meat causes breast cancer
(Natural News) The jury is in and the verdict is final: Processed meats like bacon, salami and sausage all increase breast cancer risk. A metanalysis of all 15 previously conducted studies on the subject, published recently in the International Journal of Cancer, has confirmed that eating processed meat is associated with a 9 percent increase... (Source: NaturalNews.com)
Source: NaturalNews.com - October 16, 2018 Category: Consumer Health News Source Type: news

FDA Approves Talazoparib in BRCA+ Breast Cancer FDA Approves Talazoparib in BRCA+ Breast Cancer
Compared with standard chemotherapy, the PARP inhibitor extended progression-free survival for patients with advanced BCRA-positive breast cancer.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 16, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA approves Pfizer advanced breast cancer med
The drug is part of a class of new medicines called PARP inhibitors, which block enzymes involved in repairing damaged DNA (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - October 16, 2018 Category: Pharmaceuticals Source Type: news

Fish oil may curb breast cancer cells growth, spread
A diet containing omega-3 fatty acids found in fish oil may help control the growth and spread of breast cancer cells, according to a study with mice. (Source: Health News - UPI.com)
Source: Health News - UPI.com - October 16, 2018 Category: Consumer Health News Source Type: news

AHA: After 2 Breast Cancer Diagnoses, Survivor Learns She Needs a New Heart
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 16, 2018 Category: Cancer & Oncology Tags: Cardiology, Oncology, News, Source Type: news